| 2D | Two-dimensional |
| 3D | Three-dimensional |
| ADME | Absorption, distribution, metabolism, and excretion |
| AHO | Hydroxamic acids inhibitors |
| BHMBx | Training set of N-benzyl-4-((heteroaryl)methyl)benzamides |
| BHMVx | Validation set of N-benzyl-4-((heteroaryl)methyl)benzamides |
| CAMD | computer-aided molecular design |
| Eint | MM enzyme–inhibitor interaction energy per residue |
| ΔΔGcom | Relative complexation GFE |
| GFE | Gibbs free energy |
| ΔΔGsol | Relative solvation GFE |
| HBA | Hydrogen bond Acceptor |
| HBD | Hydrogen bond Donor |
| HMM | Enthalpy component of GFE |
| HOA | Human oral absorption |
| HYD | Hydrophobic |
| HYDA | Hydrophobic Aliphatic |
| IC50 | Half-maximal inhibitory concentration |
| IE | Interaction energy |
| InhA | 2-trans enoyl-acyl carrier protein reductase |
| KatG | Mycobacterium tuberculosis catalase–peroxidase |
| LHP | Large hydrophobic pocket |
| LOO | Leave-one-out cross-validation |
| MM | Molecular mechanics |
| MM-PB | Molecular mechanics–Poisson–Boltzmann |
| Mt | Mycobacterium tuberculosis |
| MtInhA | 2-trans enoyl-acyl carrier protein reductase of Mycobacterium tuberculosis |
| PDB | Protein Data Bank |
| PfEACP | 2-trans enoyl-acyl carrier protein reductase of Plasmodium falciparum |
| PH4 | Pharmacophore |
| QSAR | Quantitative structure–activity relationships |
| RMSD | Root-mean square deviation |
| SAR | Structure–activity relationships |
| TB | Tuberculosis |
| TS | Training set |
| VS | Validation set |